Progression-free survival and local control following stereotactic ablative radiotherapy for up to 5 oligometastases: an analysis from the population-based phase II SABR-5 trial.
暂无分享，去创建一个
N. Chng | S. Tyldesley | Mengxing Liu | R. Olson | A. Bergman | D. Schellenberg | A. Alexander | Q. Matthews | H. Carolan | S. Baker | C. Lund | B. Mou | S. Atrchian | G. Arbour | W. Jiang | A. Benny